Phase II Study of FOLFIRI Plus Bevacizumab (AVASIRI) in Patients as Second Line Chemotherapy of Unresectable Colorectal Cancer

ABSTRACT: Interventions: 5-FU, CPT-11, Bevacizumab Primary outcome(s): Assessment of overall response rate (ORR; complete response [CR] + partial response [PR]). Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2616560 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR